Ken Griffin Ionis Pharmaceuticals Inc Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 145,200 shares of IONS stock, worth $6.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

145,200

Previous 137,800 5.37%

Holding current value

$6.21 Million

Previous $5.97 Million 15.85%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$36.45 - $47.7 $20 Million - $26.2 Million	549,003 Added 703.58%	627,033 $29.9 Million
Q1 2024 May 15, 2024	SELL	$42.03 - $53.55 $7.33 Million - $9.34 Million	-174,498 Reduced 69.1%	78,030 $3.38 Million
Q4 2023 Feb 14, 2024	SELL	$43.39 - $51.63 $12.3 Million - $14.6 Million	-283,390 Reduced 52.88%	252,528 $12.8 Million
Q3 2023 Nov 14, 2023	SELL	$38.5 - $47.13 $7.16 Million - $8.76 Million	-185,860 Reduced 25.75%	535,918 $24.3 Million
Q2 2023 Aug 14, 2023	BUY	$34.73 - $43.33 $19.8 Million - $24.7 Million	570,255 Added 376.35%	721,778 $29.6 Million
Q1 2023 May 15, 2023	SELL	$33.58 - $41.2 $8.19 Million - $10.1 Million	-244,023 Reduced 61.69%	151,523 $5.42 Million
Q4 2022 Feb 14, 2023	SELL	$37.12 - $46.52 $842,104 - $1.06 Million	-22,686 Reduced 5.42%	395,546 $14.9 Million
Q3 2022 Nov 14, 2022	SELL	$36.54 - $48.66 $2.26 Million - $3.01 Million	-61,911 Reduced 12.89%	418,232 $18.5 Million
Q2 2022 Aug 15, 2022	SELL	$31.71 - $43.0 $24.2 Million - $32.9 Million	-764,381 Reduced 61.42%	480,143 $17.8 Million
Q1 2022 May 16, 2022	BUY	$29.88 - $37.04 $685,835 - $850,179	22,953 Added 1.88%	1,244,524 $46.1 Million
Q4 2021 Feb 14, 2022	BUY	$25.61 - $35.1 $4.4 Million - $6.03 Million	171,714 Added 16.36%	1,221,571 $37.2 Million
Q3 2021 Nov 15, 2021	BUY	$33.54 - $40.55 $16.9 Million - $20.5 Million	504,377 Added 92.46%	1,049,857 $35.2 Million
Q2 2021 Aug 16, 2021	BUY	$34.54 - $47.25 $13 Million - $17.7 Million	375,631 Added 221.16%	545,480 $21.8 Million
Q1 2021 May 17, 2021	SELL	$42.51 - $63.78 $19.3 Million - $29 Million	-455,141 Reduced 72.82%	169,849 $7.64 Million
Q4 2020 Feb 16, 2021	SELL	$45.3 - $60.27 $60.9 Million - $81 Million	-1,344,523 Reduced 68.27%	624,990 $35.3 Million
Q3 2020 Nov 16, 2020	BUY	$47.45 - $62.95 $33.5 Million - $44.5 Million	706,888 Added 55.99%	1,969,513 $93.5 Million
Q2 2020 Aug 14, 2020	SELL	$46.85 - $61.05 $22.3 Million - $29.1 Million	-476,367 Reduced 27.39%	1,262,625 $74.4 Million
Q1 2020 May 15, 2020	BUY	$41.6 - $63.4 $52.9 Million - $80.6 Million	1,271,995 Added 272.38%	1,738,992 $82.2 Million
Q4 2019 Feb 14, 2020	BUY	$53.85 - $65.27 $22.5 Million - $27.3 Million	417,717 Added 847.64%	466,997 $28.2 Million
Q3 2019 Nov 14, 2019	SELL	$59.06 - $72.15 $31.5 Million - $38.5 Million	-533,549 Reduced 91.54%	49,280 $2.95 Million
Q2 2019 Aug 14, 2019	BUY	$62.09 - $86.14 $26.6 Million - $36.8 Million	427,750 Added 275.83%	582,829 $37.5 Million
Q1 2019 May 15, 2019	BUY	$52.92 - $81.17 $2.65 Million - $4.07 Million	50,125 Added 47.76%	155,079 $0
Q4 2018 Feb 14, 2019	BUY	$43.37 - $59.54 $3.07 Million - $4.21 Million	70,691 Added 206.32%	104,954 $5.67 Million
Q3 2018 Nov 13, 2018	SELL	$42.88 - $53.7 $990,656 - $1.24 Million	-23,103 Reduced 40.27%	34,263 $0
Q2 2018 Aug 10, 2018	SELL	$40.53 - $50.7 $11.9 Million - $14.9 Million	-294,487 Reduced 83.7%	57,366 $0
Q1 2018 May 11, 2018	BUY	$44.08 - $55.05 $9.19 Million - $11.5 Million	208,395 Added 145.27%	351,853 $15.5 Million
Q4 2017 Feb 09, 2018	BUY	$50.3 - $64.39 $7.22 Million - $9.24 Million	143,458	143,458 $7.22 Million

Others Institutions Holding IONS

# of Institutions

394

Shares Held

125M

Call Options Held

2.25M

Put Options Held

510K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $6.07B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account